Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 10/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542036 | 0.74 | MEN1 (0.39) | CARM1PRMT6 | |
| SCHEMBL9900458 | 0.73 | MRGPRX4 (0.40) | TTRHTR2ASLC6A4KCNH2DAO | |
| SCHEMBL6157137 | 0.73 | HSPB1 (0.54) | TTRHTR2ASLC6A4KCNH2 | |
| SCHEMBL6158567 | 0.73 | DAO (0.52) | TTRDAO | |
| SCHEMBL6159854 | 0.70 | SOS1 (0.50) | TTRHTR2ASLC6A4KCNH2 | |
| SCHEMBL10737281 | 0.70 | TTR (0.44) | TTRHTR2ASLC6A4KCNH2 | |
| SCHEMBL10878389 | 0.70 | TTR (0.47) | TTRHTR2ASLC6A4KCNH2DAO | |
| SCHEMBL10878563 | 0.70 | TTR (0.47) | TTRHTR2ASLC6A4KCNH2 | |
| SCHEMBL9501898 | 0.70 | DHFR (0.50) | TTR | |
| Hydrochloric Acid SCHEMBL10871226 | 0.70 | TDP1 (0.49) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | PC, GOT2, SDHA | TTR 2971/4885HTR2A 2867/4885SLC6A4 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.